Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 8/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 7/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 7/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25480405 | 1.00 | GNAO1 (0.40) | GNAO1GNAI3GNAI1KCNH2CHRM3 | |
| SCHEMBL23945861 | 0.96 | GNAO1 (0.40) | GNAO1GNAI3GNAI1KCNH2CHRM3 | |
| SCHEMBL25728848 | 0.94 | GNAO1 (0.43) | GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL25829707 | 0.93 | GNAO1 (0.40) | GNAO1GNAI3GNAI1KCNH2CHRM3 | |
| SCHEMBL25884545 | 0.91 | GNAO1 (0.43) | GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL25123296 | 0.90 | GNAO1 (0.36) | GNAO1GNAI3GNAI1KCNH2CHRM3 | |
| SCHEMBL23807056 | 0.90 | GNAO1 (0.36) | GNAO1GNAI3GNAI1 | |
| SCHEMBL25730568 | 0.90 | GNAO1 (0.46) | GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL25833708 | 0.88 | GNAO1 (0.47) | GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL25707751 | 0.87 | GNAO1 (0.38) | GNAO1GNAI3GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GNAO1 2977/4885GNAI3 1664/4885GNAI1 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.